Two former executives of Eatontown, N.J.-based Heritage Pharmaceuticals reached a settlement with 41 states after pleading guilty to fixing drug prices, reports Reuters.
Here are four things to know.
- Jason Malek, former president of Heritage, and Jeffrey Glazer, former chairman and CEO of the drug company, were charged in December for conspiring to fix generic drug prices.
- Prosecuters alleged the two executives participated in a scheme to fix prices for the antibiotic doxycycline hyclate and the diabetes medication glyburide, artificially driving up costs for patients.
- In January, the two men pled guilty to the federal criminal charges, reports Reuters.
- As part of the settlement, Mr. Malek and Mr. Glazer will each pay a $25,000 civil penalty and cooperate with an ongoing state investigation, according to the report.
More articles on supply chain:
Biogen offshoot to acquire rare disease biotech for $400M: 4 things to know
Why FDA's newest approval paves the way for precision medicine
Supply chain tip of the day: How pharmacy can drive revenue for a health system post-merger